By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Novartis Pharma AG 

Lichtstrasse 35

Basel    CH-4002  Switzerland
Phone: 41-61-324-111 Fax: 41-61-324-8001




Beyond Genomics, Inc. 

Emisphere Technologies, Inc.  Salmon calcitonin

Company News
Ophthotech Corporation (OPHT) Achieves Second $50 Million Enrollment Milestone Under Ex-US Licensing And Commercial Agreement With Novartis Pharma AG (NVS) For Fovista 3/10/2015 11:37:17 AM
Proteus Digital Health, Inc. Grows Leadership Team And Board Of Directors With Former Executives From Novartis Pharma AG (NVS), Novartis Pharma AG (NVS) And Egreetings Network 4/16/2014 9:33:11 AM
Unigene Laboratories, Inc. (UGNE) Announces Novartis Pharma AG (NVS)' Disclosure of First Interpretable Results from Phase 3 Trial of Calcitonin (SMC021) in the Treatment of Post-menopausal Osteoporosis 11/14/2011 7:08:13 AM
Novartis Pharma AG (NVS) Selects Veeva Systems, Inc. CRM for Global Deployments 10/19/2010 10:41:35 AM
Emisphere Technologies, Inc. (EMIS), Novartis Pharma AG (NVS). Nordic Bioscience A/S Provide Update on Osteoarthritis Phase III Study With Oral Calcitonin; Drug Deemed Safe But Not Effective, Emisphere Stock Falls 61.15% at 1:37PM EDT 7/23/2010 7:08:08 AM
Emisphere Technologies, Inc. (EMIS) Announces Expanded Collaboration Agreement With Novartis Pharma AG (NVS) and Cancellation of Convertible Promissory Note 6/4/2010 9:58:37 AM
Titan Pharmaceuticals (TTP) Provides Estimate of Upcoming Royalty Payment 4/22/2010 10:51:38 AM
Emisphere Technologies, Inc. (EMIS) Partner Initiates Second Phase I Trial for Oral PTH Therapy for the Treatment of Postmenopausal Osteoporosis 4/15/2010 9:55:23 AM
Novartis Pharma AG (NVS) Reports Positive Results From Phase II LCZ696 Trial 3/17/2010 9:00:25 AM
Emisphere Technologies, Inc. (EMIS) Announces Extension of Maturity Date for Novartis Pharma AG (NVS) Convertible Promissory Note 11/30/2009 9:11:56 AM